Argos Therapeutics - Company & Market Research Reports

Argos Therapeutics develops individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on Arcelis, its proprietary technology platform. In addition, its development stage products include AGS-003, for the treatment of metastatic renal cell carcinoma; and AGS-004, for the treatment of human immunodeficiency virus. Argos Therapeutics was founded in 1997 and is headquartered in Durham, North Carolina.

Cancer Immunomodulators Market & Pipeline Insight 2020 - Product Thumbnail Image

Cancer Immunomodulators Market & Pipeline Insight 2020

  • Drug Pipelines
  • 1000 Pages
From
Bladder and Ureter Cancer Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Bladder and Ureter Cancer Drug Development Pipeline Review, 2017

  • Report
  • 150 Pages
From
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2018 - Product Thumbnail Image

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2018

  • Drug Pipelines
  • 1005 Pages
From
Global Cancer Monoclonal Antibodies Market 2017-2021 - Product Thumbnail Image

Global Cancer Monoclonal Antibodies Market 2017-2021

  • Report
  • 115 Pages
From
Global Lung Cancer Vaccine Market & Pipeline Outlook 2022 - Product Thumbnail Image

Global Lung Cancer Vaccine Market & Pipeline Outlook 2022

  • Report
  • 150 Pages
From
Global Dendritic Cell Cancer Vaccine Market & Clinical Trials Outlook 2023 - Product Thumbnail Image

Global Dendritic Cell Cancer Vaccine Market & Clinical Trials Outlook 2023

  • Report
  • 170 Pages
From
Global Dendritic Cell Cancer Vaccine Market Dosage Price & Clinical Trials Outlook 2024 - Product Thumbnail Image

Global Dendritic Cell Cancer Vaccine Market Dosage Price & Clinical Trials Outlook 2024

  • Report
  • 255 Pages
From
Diabetes & Obesity Drug Development Pipeline Review, 2016 - Product Thumbnail Image

Diabetes & Obesity Drug Development Pipeline Review, 2016

  • Report
  • 560 Pages
From
HIV / AIDS - Pipeline Review, H1 2016 - Product Thumbnail Image

HIV / AIDS - Pipeline Review, H1 2016

  • Drug Pipelines
  • 886 Pages
From
HIV-1 Infection - Pipeline Review, H2 2015 - Product Thumbnail Image

HIV-1 Infection - Pipeline Review, H2 2015

  • Drug Pipelines
  • 406 Pages
From
HIV / AIDS - Pipeline Review, H2 2015 - Product Thumbnail Image

HIV / AIDS - Pipeline Review, H2 2015

  • Drug Pipelines
  • 916 Pages
From
T-Cell Immunotherapy Market (2nd Edition), 2017-2030 - Product Thumbnail Image

T-Cell Immunotherapy Market (2nd Edition), 2017-2030

  • Report
  • 654 Pages
From
HIV / AIDS - Pipeline Review, H1 2015 - Product Thumbnail Image

HIV / AIDS - Pipeline Review, H1 2015

  • Drug Pipelines
  • 871 Pages
From
T-Cell Immunotherapy Market (3rd Edition), 2018-2030 - Product Thumbnail Image

T-Cell Immunotherapy Market (3rd Edition), 2018-2030

  • Report
  • 850 Pages
From
HIV-1 Infection - Pipeline Review, H1 2015 - Product Thumbnail Image

HIV-1 Infection - Pipeline Review, H1 2015

  • Drug Pipelines
  • 319 Pages
From
Global & USA Cancer Immunotherapy Market Analysis & Forecast to 2022 - Product Thumbnail Image

Global & USA Cancer Immunotherapy Market Analysis & Forecast to 2022

  • Report
  • 370 Pages
From
Systemic Lupus Erythematosus - Pipeline Insight, 2018 - Product Thumbnail Image

Systemic Lupus Erythematosus - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
Dermatology Therapeutics Drug Development Pipeline Review, 2016 - Product Thumbnail Image

Dermatology Therapeutics Drug Development Pipeline Review, 2016

  • Report
  • 432 Pages
From
Renal Cell Carcinoma - Pipeline Review, H2 2016 - Product Thumbnail Image

Renal Cell Carcinoma - Pipeline Review, H2 2016

  • Drug Pipelines
  • 793 Pages
From
Dendritic Cell and CAR-T Therapies, 2014 - 2024 - Product Thumbnail Image

Dendritic Cell and CAR-T Therapies, 2014 - 2024

  • Drug Pipelines
  • 187 Pages
From
Loading Indicator
adroll